OTCM
PMCUF
Market cap13bUSD
, Last price
Name
Pro Medicus Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Richmond, Australia, and established in 1983, Pro Medicus Limited is a leading developer and provider of cutting-edge healthcare imaging software and support services. The company caters to a diverse range of medical institutions, including hospitals and diagnostic imaging facilities, across Australia, North America, and Europe. Its comprehensive product suite features a proprietary Radiology Information System (RIS), designed for efficient practice management, which comes complete with training, installation, professional services, and ongoing post-sales support (marketed under names like Visage RIS). Additionally, Pro Medicus offers Promedicus.net, an e-health platform, and advanced healthcare imaging software that empowers radiologists and clinicians with robust visualization capabilities for 2D, 3D, and 4D medical images, alongside its Picture Archiving and Communication System (PACS)/digital imaging solutions (e.g., Visage 7). The company also provides integration products and the Visage Ease Pro mobile application, allowing users to remotely interpret diagnostic imaging studies stored on a Visage 7 server.
Key people
Peter Kempen
Non-Executive Independent Chairman of the Board · since 2010
Sam Hupert
Chief Executive Officer, Managing Director, Executive Director · since 2010
Clayton Hatch
Chief Financial Officer · since 2023
Malte Westerhoff
General Manager Europe and Global Chief Technology Officer · since 2023
Brad Levin
General Manager - North America and Global Head of Marketing · since 2023
Danny Tauber
General Manager - Australia · since 2011
Anthony Hall
Technology Director, Executive Director
Teresa Gschwind
Global Head - Customer Service
Sean Lambright
Global Head of Sales - Visage Imaging Inc
Sharni Redenbach
People and Culture Director · since 2022
Danny English
Company Secretary · since 2023
Leigh Farrell
Non-Executive Independent Director · since 2017
Non-Executive Independent Director · since 2016
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2021
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||